AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

被引：42
|
作者：
Fong, P. C.
Boss, D. S.
Carden, C. P.
Roelvink, M.
De Greve, J.
Gourley, C. M.
Carmichael, J.
De Bono, J. S.
Schellens, J. H.
Kaye, S. B.
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] UZ Brussel, Ctr Oncol, Brussels, Belgium
[4] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[5] Kudos Pharmaceut, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5510
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5510
引用
收藏
页数：1
相关论文
共 50 条
  • [11] The Poly (ADP-Ribose) Polymerase-1 Inhibitor, AZD2281, enhances radiation response of breast cancer cells by inhibiting DNA repair
    Mehta, Meghna
    Munshi, Anupama
    CANCER RESEARCH, 2012, 72
  • [12] A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
    Liu, Joyce F.
    Tolaney, Sara M.
    Birrer, Michael
    Fleming, Gini F.
    Buss, Mary K.
    Dahlberg, Suzanne E.
    Lee, Hang
    Whalen, Christin
    Tyburski, Karin
    Winer, Eric
    Ivy, Percy
    Matulonis, Ursula A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (14) : 2972 - 2978
  • [13] The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer
    Kathleen Moore
    Zhi-Yi Zhang
    Shefali Agarwal
    Howard Burris
    Manish R. Patel
    Vikram Kansra
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 497 - 503
  • [14] The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer
    Moore, Kathleen
    Zhang, Zhi-Yi
    Agarwal, Shefali
    Burris, Howard
    Patel, Manish R.
    Kansra, Vikram
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (03) : 497 - 503
  • [15] PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS
    Kaye, S.
    Kaufman, B.
    Lubinski, J.
    Matulonis, U.
    Gourley, C.
    Karlan, B.
    Taylor, D.
    Wickens, M.
    Carmichael, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 304 - 304
  • [16] Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020
    Madariaga, Ainhoa
    Bonilla, Luisa
    McMullen, Michelle
    Oza, Amit M.
    Lheureux, Stephanie
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (08) : 1256 - 1257
  • [17] Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients
    Sandhu, S. K.
    Wilding, G.
    Schelman, W. R.
    Omlin, A.
    Kreischer, N.
    Carpenter, C.
    Iannone, R.
    Kaye, S.
    de-Bono, J. S.
    Wenham, R. M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 107 - 108
  • [18] Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms
    Valenza, C.
    Mongillo, M.
    Gigli, F.
    Trapani, D.
    Katrini, J.
    Nicolo, E.
    Boldrini, L.
    Bielo, L. Boscolo
    Castellano, G.
    Guidi, L.
    Pellizzari, G.
    Derio, S.
    Lapresa, M.
    Parma, G.
    Derenzini, E.
    Curigliano, G.
    Colombo, N.
    ESMO OPEN, 2024, 9 (09)
  • [19] A phase I trial of veliparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), and topotecan (TPT) in patients with solid tumors.
    Hendrickson, Andrea Elisabeth Wahner
    Menefee, Michael E.
    Hartmann, Lynn C.
    Long, Harry J.
    Northfelt, Donald W.
    Reid, Joel M.
    Boakye-Agyeman, Fleix
    Flatten, Karen S.
    Poirier, Guy G.
    Lensing, Janet
    Erlichman, Charles
    Kaufmann, Scott H.
    Haluska, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [20] First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.
    Sandhu, S. K.
    Wenham, R. M.
    Wilding, G.
    McFadden, M.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Carpenter, C. L.
    De Bono, J. S.
    Schelman, W. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345